Exploring the Impact of Comorbid Type 2 Diabetes on Prediction Models Using Blood Biomarkers for Determining Alzheimer’s Disease Diagnosis
Juhi Dalal1, Lucy Xin1, Fan Zhang2, James Hall2, Melissa Petersen2
1University of North Texas Health Fort Worth – Texas College of Osteopathic Medicine, 2University of North Texas Fort Worth - Texas College of Osteopathic Medicine; Department of Family Medicine; Institute for Translational Research
Objective:

The study aims to determine whether diabetes impacts Alzheimer’s disease [AD] blood biomarkers in a manner that may contribute to false-positive indications of AD in diagnostic models.

Background:
AD is linked with a number of medical comorbidities including type 2 diabetes. This is the case as increased insulin resistance, a hallmark of diabetes, has been associated with cognitive impairment, a key AD clinical feature. Currently, limited research has examined the extent to which having a diabetes diagnosis impacts the relationship and utility of blood biomarkers commonly used in AD diagnosis.
Design/Methods:

Baseline data were analyzed among n=354 non-Hispanic Whites[NHW] (n=54 diabetic), n=293 Hispanics (n=92 diabetic), and n=729 non-Hispanic Blacks[NHB] (n=188 diabetic) participants involved in the Health and Aging Brain Study-Health Disparities (HABS-HD). Plasma biomarkers Aβ40, Aβ42, Total tau, neurofilament light chain (NfL) and ptau181 were assayed with single molecule array (SIMOA) technology. Support Vector Machine (SVM) models were conducted using plasma biomarkers to predict cognitive diagnosis (Cognitively Unimpaired[CU] or dementia). Discriminative analysis were used to identify false positives. Fisher’s Exact tests were used to explore whether the categorical variable of having diabetes was significantly associated with the false positive classification. Significance was set at p<0.05.

Results:

SVM models distinguishing CU from dementia yielded n=133 false positives (By race/ethnicity: NHB=54, Hispanic=51, NHW=28). The SVM performed at a sensitivity of 87.50%, specificity of 69.79%, and reached an area under the curve of 84.38%. Among false positive cases, there was statistical significance across all race/ethnic groups in those with diabetes (versus without) in the full and reduced models. For NHB and NHW participants, amyloid-only models showed statistical significance. For Hispanic participants, all biomarker models (full and reduced) showed statistical significance by diabetes status.

Conclusions:

These findings demonstrate that diabetes was significantly related with false-positive classifications of AD blood biomarker-based SVM models—particularly among Hispanic and Black participants.

10.1212/WNL.0000000000216328
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.